Neurocrine Biosciences Q1 adjusted EPS beats estimates, sales up 44%

Neurocrine Biosciences

05/05/2026 21:15

Overview

U.S. biopharma firm's Q1 net product sales rose 44% yr/yr, driven by INGREZZA and CRENESSITY

Adjusted EPS and adjusted net income for Q1 beat analyst expectations

Company announced deal to acquire Soleno Therapeutics for $2.9 bln, expected to close in Q2

Outlook

Company reaffirms 2026 full-year INGREZZA net sales guidance of $2.7 bln to $2.8 bln

Company expects 2026 GAAP R&D expense of $1.2 bln to $1.25 bln

2026 guidance excludes post-close expenses from Soleno Therapeutics acquisition, expected to close in Q2 2026

Result Drivers

INGREZZA DEMAND - Double-digit prescription volume growth and record new prescriptions for INGREZZA drove sales, partially offset by a lower net price

CRENESSITY LAUNCH - Strong patient demand and approximately 80% reimbursement for CRENESSITY supported sales growth

COMMERCIAL INVESTMENT - Increased SG&A expenses reflected continued investment in expanding INGREZZA and CRENESSITY sales teams

Company press release: ID:nPn4HBPRPa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Product Sales
$811 mln
Q1 Adjusted EPS
Beat
$1.94
$1.15 (16 Analysts)
Q1 EPS
$1.91
Q1 Adjusted Net Income
Beat
$200.50 mln
$131.44 mln (14 Analysts)
Q1 Net Income
$197.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Neurocrine Biosciences Inc is $181.00, about 35% above its May 4 closing price of $134.07

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 19 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)